NYSE:BSX - Boston Scientific Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Boston Scientific Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $42.62 +0.12 (+0.28 %) (As of 02/23/2020 05:08 AM ET) Add Compare Today's Range$42.04Now: $42.62▼$42.8550-Day Range$41.87MA: $43.49▼$45.7152-Week Range$34.35Now: $42.62▼$46.62Volume7.28 million shsAverage Volume7.30 million shsMarket Capitalization$59.40 billionP/E Ratio12.80Dividend YieldN/ABeta0.87 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. Read More… Industry, Sector and Symbol Stock Exchange NYSE Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:BSX Previous Symbol CUSIP10113710 CIK885725 Webhttp://www.bostonscientific.com/ Phone508-683-4000Debt Debt-to-Equity Ratio0.99 Current Ratio1.14 Quick Ratio0.77Price-To-Earnings Trailing P/E Ratio12.80 Forward P/E Ratio24.08 P/E Growth2.39 Sales & Book Value Annual Sales$10.74 billion Price / Sales5.53 Cash Flow$2.11 per share Price / Cash Flow20.20 Book Value$6.31 per share Price / Book6.75Profitability EPS (Most Recent Fiscal Year)$1.58 Net Income$4.70 billion Net Margins43.78% Return on Equity23.62% Return on Assets8.95%Miscellaneous Employees32,000 Outstanding Shares1,393,820,000Market Cap$59.40 billion Next Earnings Date4/22/2020 (Estimated) OptionableOptionable Receive BSX News and Ratings via Email Sign-up to receive the latest news and ratings for BSX and its competitors with MarketBeat's FREE daily newsletter. BSX Rates by TradingView Boston Scientific (NYSE:BSX) Frequently Asked Questions What is Boston Scientific's stock symbol? Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX." How were Boston Scientific's earnings last quarter? Boston Scientific Co. (NYSE:BSX) issued its quarterly earnings data on Wednesday, February, 5th. The medical equipment provider reported $0.46 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.44 by $0.02. The medical equipment provider earned $2.91 billion during the quarter, compared to analysts' expectations of $2.92 billion. Boston Scientific had a return on equity of 23.62% and a net margin of 43.78%. The company's revenue was up 13.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.39 earnings per share. View Boston Scientific's Earnings History. When is Boston Scientific's next earnings date? Boston Scientific is scheduled to release their next quarterly earnings announcement on Wednesday, April 22nd 2020. View Earnings Estimates for Boston Scientific. What guidance has Boston Scientific issued on next quarter's earnings? Boston Scientific issued an update on its FY20 earnings guidance on Wednesday, February, 5th. The company provided earnings per share (EPS) guidance of $1.74-1.79 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.79. What price target have analysts set for BSX? 18 equities research analysts have issued twelve-month price targets for Boston Scientific's stock. Their forecasts range from $36.20 to $58.00. On average, they anticipate Boston Scientific's share price to reach $49.48 in the next twelve months. This suggests a possible upside of 16.1% from the stock's current price. View Analyst Price Targets for Boston Scientific. What is the consensus analysts' recommendation for Boston Scientific? 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 1 hold rating, 16 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Boston Scientific. What are Wall Street analysts saying about Boston Scientific stock? Here are some recent quotes from research analysts about Boston Scientific stock: 1. Needham & Company LLC analysts commented, "BSX announced it is acquiring the private company up front cash and commercial-based milestones. Vertiflex’s Superion system is a minimally invasive device to treat patients with lumbar spinal stenosis (LSS). BSX expects the deal to be immaterial to its adjusted EPS through 2020 and accretive thereafter. While we are a little surprised to see BSX enter the spinal surgery market, there probably are synergies with its existing pain business and we see this deal as a typical BSX transaction in which it acquires an asset allowing it to go deeper within a disease state/disorder (in this case chronic pain). We expect BSX’s string of acquisitions over the past ~18 months (including Vertiflex) to combine to provide a material benefit to its longer-term organic growth and we reiterate our Strong Buy rating." (5/13/2019) 2. BTIG Research analysts commented, "$42 Story BSX results fell short of Street expectations on a myriad of items. Heading into the print, investors anticipated the paclitaxel and mesh issues but less selling days, a temporary supply issue and a weaker Neuromod result pressured Q1 incrementally. As we anticipated in our preview, BSX guided FY19 revenue growth to the bottom half of the prior range (7-8% from 7- 9%). We revised our estimates accordingly for known pressure points and while there could be upside from high-growth segments (Structural Heart remains likely), our view is that NT significant outperformance by BSX is less likely than it was six months ago. On lower forecasts and a slightly lower multiple, we trim our PT from $45 to $42. Some investors have asked if the growth acceleration story is over. We do not think so but we do think there will be a NT slowdown before potential acceleration." (4/25/2019) Has Boston Scientific been receiving favorable news coverage? News headlines about BSX stock have trended very negative this week, InfoTrie reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Boston Scientific earned a news impact score of -3.4 on InfoTrie's scale. They also gave news headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Boston Scientific. Who are some of Boston Scientific's key competitors? Some companies that are related to Boston Scientific include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX), Insulet (PODD) and Varian Medical Systems (VAR). What other stocks do shareholders of Boston Scientific own? Based on aggregate information from My MarketBeat watchlists, some companies that other Boston Scientific investors own include NVIDIA (NVDA), Alibaba Group (BABA), Visa (V), Bank of America (BAC), Walt Disney (DIS), Netflix (NFLX), CVS Health (CVS), AT&T (T), Micron Technology (MU) and Home Depot (HD). Who are Boston Scientific's key executives? Boston Scientific's management team includes the folowing people: Mr. Michael F. Mahoney, Chairman, Pres & CEO (Age 54)Mr. Daniel J. Brennan, Exec. VP & CFO (Age 53)Mr. Joseph M. Fitzgerald, Exec. VP & Pres of Rhythm Management (Age 55)Mr. David A. Pierce, Exec. VP & Pres of MedSurg (Age 55)Mr. Kevin J. Ballinger, Exec. VP & Pres of Interventional Cardiology (Age 46) Who are Boston Scientific's major shareholders? Boston Scientific's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (9.15%), Capital World Investors (7.73%), Wealth Quarterback LLC (7.26%), State Street Corp (4.32%), Janus Henderson Group PLC (2.78%) and Bollard Group LLC (2.38%). Company insiders that own Boston Scientific stock include Arthur C Butcher, Daniel J Brennan, David A Pierce, Desiree Ralls-Morrison, Edward F Mackey, Eric Francis Yves Thepaut, Halliday Hamish, Jeffrey B Mirviss, Jodi Euerle Eddy, John Bradley Sorenson, John E Sununu, Joseph Michael Fitzgerald, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Wendy Carruthers, Williamson Scott, Xin Warren Wang and Yoshiaki Fujimori. View Institutional Ownership Trends for Boston Scientific. Which institutional investors are selling Boston Scientific stock? BSX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Fred Alger Management LLC, Senator Investment Group LP, Bessemer Group Inc., WCM Investment Management LLC, Bank of New York Mellon Corp, Marshall Wace North America L.P. and AustralianSuper Pty Ltd. Company insiders that have sold Boston Scientific company stock in the last year include Arthur C Butcher, Daniel J Brennan, David A Pierce, Desiree Ralls-Morrison, Edward F Mackey, Eric Francis Yves Thepaut, Jeffrey B Mirviss, Jodi Euerle Eddy, John Bradley Sorenson, Joseph Michael Fitzgerald, Kevin J Ballinger, Maulik Nanavaty, Wendy Carruthers and Xin Warren Wang. View Insider Buying and Selling for Boston Scientific. Which institutional investors are buying Boston Scientific stock? BSX stock was bought by a variety of institutional investors in the last quarter, including Wealth Quarterback LLC, Jennison Associates LLC, Assenagon Asset Management S.A., Massachusetts Financial Services Co. MA, State Street Corp, Strs Ohio, TCW Group Inc. and Westfield Capital Management Co. LP. Company insiders that have bought Boston Scientific stock in the last two years include John E Sununu and Williamson Scott. View Insider Buying and Selling for Boston Scientific. How do I buy shares of Boston Scientific? Shares of BSX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Boston Scientific's stock price today? One share of BSX stock can currently be purchased for approximately $42.62. How big of a company is Boston Scientific? Boston Scientific has a market capitalization of $59.40 billion and generates $10.74 billion in revenue each year. The medical equipment provider earns $4.70 billion in net income (profit) each year or $1.58 on an earnings per share basis. Boston Scientific employs 32,000 workers across the globe.View Additional Information About Boston Scientific. What is Boston Scientific's official website? The official website for Boston Scientific is http://www.bostonscientific.com/. How can I contact Boston Scientific? Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-683-4000 or via email at [email protected] MarketBeat Community Rating for Boston Scientific (NYSE BSX)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 843 (Vote Outperform)Underperform Votes: 727 (Vote Underperform)Total Votes: 1,570MarketBeat's community ratings are surveys of what our community members think about Boston Scientific and other stocks. Vote "Outperform" if you believe BSX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BSX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/23/2020 by MarketBeat.com StaffFeatured Article: What does cost of debt say about a company’s financial health?
